Sen. Grassley Wants FDA To Give More Info To CMS, Cites Menaflex Case

Controversy over FDA's 2008 clearance of ReGen Biologics' Menaflex knee repair device has now expanded into questions from Congress over how effectively FDA shares information with its sister agency CMS